| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Seres Therapeutics Inc (NASDAQ: MCRB)
MCRB Technical Analysis
5
| As on 26th Dec 2024 MCRB STOCK Price closed @ 0.92 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.72 & Strong Sell for SHORT-TERM with Stoploss of 3.72 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MCRBSTOCK Price
| Open | 0.94 | Change | Price | % |
| High | 0.97 | 1 Day | -0.04 | -4.17 |
| Low | 0.92 | 1 Week | 0.03 | 3.37 |
| Close | 0.92 | 1 Month | 0.26 | 39.39 |
| Volume | 885222 | 1 Year | -3.60 | -79.65 |
| 52 Week High 5.07 | 52 Week Low 0.56 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| LCID | 3.30 | 3.12% |
| LMDX | 0.02 | 0.00% |
| NVDA | 139.93 | -0.21% |
| AKTS | 0.04 | 0.00% |
| OPTT | 0.45 | 36.36% |
| QSI | 2.15 | 65.38% |
| TNXP | 0.37 | -5.13% |
| TSLA | 454.13 | -1.76% |
| PONO | 1.72 | 2.38% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MCRB Daily Charts |
MCRB Intraday Charts |
Whats New @ Bazaartrend |
MCRB Free Analysis |
|
|
MCRB Important Levels Intraday
| RESISTANCE | 1.02 |
| RESISTANCE | 0.99 |
| RESISTANCE | 0.97 |
| RESISTANCE | 0.95 |
| SUPPORT | 0.89 |
| SUPPORT | 0.87 |
| SUPPORT | 0.85 |
| SUPPORT | 0.82 |
MCRB Forecast December 2024
| 4th UP Forecast | 3.6 |
| 3rd UP Forecast | 2.74 |
| 2nd UP Forecast | 2.21 |
| 1st UP Forecast | 1.68 |
| 1st DOWN Forecast | 0.16 |
| 2nd DOWN Forecast | -0.37 |
| 3rd DOWN Forecast | -0.9 |
| 4th DOWN Forecast | -1.76 |
MCRB Weekly Forecast
| 4th UP Forecast | 1.77 |
| 3rd UP Forecast | 1.50 |
| 2nd UP Forecast | 1.33 |
| 1st UP Forecast | 1.16 |
| 1st DOWN Forecast | 0.68 |
| 2nd DOWN Forecast | 0.51 |
| 3rd DOWN Forecast | 0.34 |
| 4th DOWN Forecast | 0.07 |
MCRB Forecast2024
| 4th UP Forecast | 10.07 |
| 3rd UP Forecast | 7.14 |
| 2nd UP Forecast | 5.32 |
| 1st UP Forecast | 3.51 |
| 1st DOWN Forecast | -1.67 |
| 2nd DOWN Forecast | -3.48 |
| 3rd DOWN Forecast | -5.3 |
| 4th DOWN Forecast | -8.23 |
Seres Therapeutics Inc ( NASDAQ USA Symbol : MCRB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MCRB Business Profile
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Address: 200 Sidney Street, Cambridge, MA, United States, 02139
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service